The IVD Cancer Test Products market includes immunoassay and NAT (e.g., PCR and FISH) screening, diagnostic, and monitoring tests, including Fecal Occult Blood Testing (FOBT). BBC also tracks cancer testing by flow cytometry and histopathology (IHC) technologies. The NAT based Genetic Testing market includes genetic testing for CFTR, thrombophilia, HLA, and other genetic disorders. Pharmacogenetic testing, as well as analysis of chromosomal abnormalities and microdeletion disorders, is also included. Pharmacogenetic testing applications are emerging for NAT in both markets as pharmaceutical products undergo relabeling and more targeted therapies are developed (NAT).
Cancer testing is performed in the laboratory and ambulatory settings, while genetic testing is performed only in the laboratory setting.
The leading worldwide manufacturers of cancer and genetic testing products include, but are not limited to:
Due to the fragmented nature of these markets and numerous emerging competitors, BBC tracks >25 companies across various technologies.
Market Assessment/Monitoring Reports:
Relevant Conferences: